Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. (LTRN) on July 24, 2025. The registrant is a Delaware corporation with principal executive offices in Dallas, Texas, and its common stock trades on the Nasdaq Capital Market. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Appointment: The Board appointed Lee T. Schalop, M.D., as a new director. Dr. Schalop brings extensive experience as a former CEO of Oncoceutics, Inc. (sold for $450 million) and over 19 years in the financial industry at firms including Morgan Stanley and J.P. Morgan.
- By-laws Amendment: The Board approved an immediate amendment to the Company's By-laws reducing the quorum requirement for stockholder meetings from a majority of shares entitled to vote to one-third (33.33%).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this report, other than the standard implications of governance changes.
Investor Verification Checklist
- Verify the impact of the reduced quorum requirement (33.33%) on future stockholder meeting outcomes and potential activist investor influence.
- Review Dr. Schalop's full background and potential conflicts of interest given his recent role as a Board Observer at Chimerix Inc. until April 2025.
- Confirm the effective date of the By-laws amendment and any related proxy statement filings.